SITAGLIPTIN PHOSPHATE - Generic Drug Details

What are the generic sources for sitagliptin phosphate and what is the scope of patent protection?

Sitagliptin phosphate is the generic ingredient in two branded drugs marketed by Merck Sharp Dohme, Apotex, Sandoz, and Watson Labs Inc, and is included in four NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sitagliptin phosphate has fifty-two patent family members in forty countries.

There are thirty-four drug master file entries for sitagliptin phosphate. Three suppliers are listed for this compound. There are fifteen tentative approvals for this compound.

Summary for SITAGLIPTIN PHOSPHATE

International Patents:	52
US Patents:	1
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	34
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	46
Drug Prices:	Drug price trends for SITAGLIPTIN PHOSPHATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SITAGLIPTIN PHOSPHATE
DailyMed Link:	SITAGLIPTIN PHOSPHATE at DailyMed

See drug prices for SITAGLIPTIN PHOSPHATE

Recent Clinical Trials for SITAGLIPTIN PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanfang Hospital, Southern Medical University	PHASE4
Zhibin Xu	PHASE4
University of Lahore	PHASE3

See all SITAGLIPTIN PHOSPHATE clinical trials

Generic filers with tentative approvals for SITAGLIPTIN PHOSPHATE

Applicant	Application No.	Strength	Dosage Form
		50MG;1000MG	TABLET;ORAL
		50MG;500MG	TABLET;ORAL
		100MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SITAGLIPTIN PHOSPHATE

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Medical Subject Heading (MeSH) Categories for SITAGLIPTIN PHOSPHATE

Dipeptidyl-Peptidase IV Inhibitors

Hypoglycemic Agents

Incretins

Anatomical Therapeutic Chemical (ATC) Classes for SITAGLIPTIN PHOSPHATE

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for SITAGLIPTIN PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUVIA	Tablets	sitagliptin phosphate	50 mg/10 mg 50 mg/20 mg 50 mg/40 mg	021995	1	2012-11-06
JANUVIA	Tablets	sitagliptin phosphate	100 mg/20 mg	021995	1	2012-06-25
JANUVIA	Tablets	sitagliptin phosphate	100 mg/10 mg and 100 mg/40 mg	021995	1	2012-06-19
JANUVIA	Tablets	sitagliptin phosphate	25 mg, 50 mg and 100 mg	021995	6	2010-10-18

US Patents and Regulatory Information for SITAGLIPTIN PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202387-002	Jan 14, 2026	AB	RX	No	No
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	AB	RX	Yes	No	7,326,708*PED				Y
Sandoz	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202387-003	Jan 14, 2026	AB	RX	No	No
Watson Labs Inc	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202327-001	Dec 30, 2025	AB	RX	No	No
Apotex	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202425-001	Jan 20, 2026	AB	RX	No	No
Watson Labs Inc	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202327-003	Dec 30, 2025	AB	RX	No	No

Expired US Patents for SITAGLIPTIN PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	7,459,428
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	6,303,661
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	6,890,898
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-002	Oct 16, 2006	6,890,898
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	6,303,661
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	7,078,381

International Patents for SITAGLIPTIN PHOSPHATE

Country	Patent Number	Title	Estimated Expiration
Montenegro	00405	So fosforne kiseline i inhibitora dipeptidil peptidaze-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)
Dominican Republic	P2004000941	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV
Slovenia	1654263
Malaysia	139595	PHOSPHORIC ACID SALT OF A DIPEPTIDYL - IV INHIBITOR
South Korea	101013431
Iceland	8183	Fosfórsýru salt af dípeptídýl peptíðasa-IV hindra

Supplementary Protection Certificates for SITAGLIPTIN PHOSPHATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	PA2014041	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-024, 2007 03 21 EU/1/07/382/001-024 20070321
0896538	91334	Luxembourg		CERTIFICATE TITLE: SITAGLIPTIN, OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER LE SEL PHOSPHATE (JANUVIA); FIRST REGISTRATION: 20070321
1412357	C200700039	Spain		PRODUCT NAME: SITAGLIPTINA; NATIONAL AUTHORISATION NUMBER: EU/1/07/383/001-018; DATE OF AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001-018; DATE OF FIRST AUTHORISATION IN EEA: 20070321
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
1412357	91360	Luxembourg		PRODUCT NAME: SITAGLIPTIN; AUTHORISATION NUMBER AND DATE: EU/1/07/383/001-018 20070323
1412357	PA2007006	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321

Market Dynamics and Financial Trajectory for Sitagliptin Phosphate

Last updated: February 19, 2026

What is the current market landscape for Sitagliptin Phosphate?

Sitagliptin phosphate is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor prescribed for type 2 diabetes mellitus (T2DM). It is marketed primarily under the brand name Januvia by Merck & Co. Since its approval in 2006 by the U.S. Food and Drug Administration (FDA), it has become a top-selling oral antidiabetic agent.

The global diabetes medications market was valued at approximately $50 billion in 2022, with DPP-4 inhibitors accounting for roughly 30% of that market. Sitagliptin ranks as a leading product within this segment, with global sales surpassing $7 billion in 2022, according to IQVIA data.

Patent Status and Generic Entry

Sitagliptin phosphate's original patent expired in most major markets by 2022, which led to increased competition from generics. The expiration has introduced several low-cost alternatives, affecting revenue streams for the originator.

Market Penetration and Patient Adoption

Januvia remains dominant in North America, with a market share estimated at 45% for DPP-4 inhibitors. In Europe and Asia, generic versions have captured significant market segments; for example, India and China have seen increased usage of generic sitagliptin products, which are priced substantially lower.

How do regulatory and pricing policies influence Sitagliptin’s financial trajectory?

Regulatory Approvals

Sitagliptin gained approval in multiple jurisdictions shortly after the FDA in 2006. The European Medicines Agency (EMA) approved it in 2007; China approved it in 2009. Licensing expanded to over 100 countries, but regulatory hurdles for generics have increased, especially regarding bioequivalence evidence.

Patent Litigation and Exclusivity

Merck’s patent protection extended until 2022 in the U.S. and until 2021 in Europe, influencing pricing and market control. Patent challenges from generics notably started from 2020 onwards, reducing exclusivity and pressuring prices.

Pricing Dynamics

In markets with nationalized healthcare or strict drug pricing regulations, Sitagliptin's costs are capped, leading to narrower margins. In contrast, in the U.S., branded prices ranged from $300 to $400 per month in 2022, although insurance and pharmacy benefit managers often reduce out-of-pocket costs, impacting net revenue.

What are the key drivers affecting market growth and revenue?

Increasing Global Prevalence of T2DM

World diabetes prevalence has increased from 463 million in 2019 to 537 million in 2021, expected to reach 700 million by 2045 (IDF, 2021). This rise expands the potential patient pool for sitagliptin and other antidiabetic agents.

Competitive Landscape

The emergence of drugs like SGLT2 inhibitors (e.g., empagliflozin) and GLP-1 receptor agonists (e.g., semaglutide) presents competition. These agents often demonstrate superior cardiovascular benefits and weight loss advantages, influencing prescribing patterns.

Pipeline and Line-Extension Strategies

Merck has developed fixed-dose combinations, for instance, with metformin and saxagliptin, to sustain market relevance. Their regulatory submissions, including the addition of formulations targeting specific populations (e.g., Asian patients), could prolong revenue from sitagliptin-based products.

Impact of Biosimilars and Generics

As patents faded, biosimilar and generic sitagliptin products gain market share. These alternatives, with price discounts of up to 70%, have eroded profit margins and volume sales for original patent-holders.

What financial projections can be anticipated for sitagliptin?

Revenue Trends

From a peak exceeding $7 billion in 2022, sales are projected to decline at a compound annual growth rate (CAGR) of approximately 10% through 2025 owing to generic competition, falling to roughly $4 billion by 2025.

Cost Structures

Pricing erosion will likely lead to reduced gross margins, with net profit margins narrowing from approximately 25% pre-patent expiry to near 10% post-generic entry, depending on manufacturing costs and market-specific reimbursement policies.

Strategic Adjustments

Pharmaceutical companies are increasing investment in combination therapies and exploring new indications to offset declining sitagliptin revenues. Development of fixed-dose combinations is anticipated to generate additional sales, but their contribution may only partially compensate for declines in standalone sitagliptin.

How do geographic variations influence revenue prospects?

Region	Market Size (2022)	Patent Status	Generic Penetration	Pricing Dynamics
North America	$4.5 billion	Patented until 2022	Moderate	Higher prices; significant branded revenue
Europe	$1.2 billion	Patents expired in 2021	High	Price pressure from biosimilars and generics
Asia	$1.3 billion	Variable; some markets patent-protected	High	Lower prices; rapid adoption of generics

Growing markets such as India and China are likely to see exponential growth in generic sitagliptin sales, but at lower price points, influencing global revenue distribution.

Key takeaways

• Sitagliptin phosphate remains a leading antidiabetic drug but faces revenue decline due to patent expiration and generic competition.
• The global rise in T2DM prevalence supports continued demand, although shifting prescription patterns favor newer agents with cardiovascular benefits.
• Pricing pressures in regulated markets and biosimilar entry in emerging markets compress profit margins.
• Merck and competitors focus on combination drugs and novel formulations to sustain market relevance.
• The overall financial trajectory indicates a declining revenue trend unless new indications or pipeline innovations emerge.

FAQs

1. What factors caused the decline in sitagliptin sales after 2022?
Patent expiration led to generic competition, significantly reducing prices and sales volumes in major markets.

2. Are there new formulations of sitagliptin expected to extend its market life?
Yes, fixed-dose combinations and formulations targeting specific populations are under regulatory review, which could bolster sales.

3. How does competition from SGLT2 and GLP-1 drugs affect sitagliptin's market?
These drugs offer cardiovascular and weight-loss benefits, making them preferred options, thereby reducing sitagliptin’s market share.

4. What is the potential for growth in emerging markets?
Rapid adoption of generics and lower pricing in Asia and Africa could stabilize or slightly increase total sales but not fully offset declines in developed markets.

5. What strategies are companies employing to mitigate revenue losses?
Investments in combination therapies, expanding indications, and geographic expansion aim to prolong profitability.

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://www.diabetesatlas.org
2. IQVIA. (2022). Market Data Reports on Diabetes Medications.
3. U.S. Food and Drug Administration. (2006). FDA Approves Januvia for Type 2 Diabetes.
4. European Medicines Agency. (2007). EMA Approval of Sitagliptin.
5. Merck & Co. Annual Reports. (2022). Financial Statements and Market Analysis.